The impact of hormones in autoimmune cutaneous diseases

References

• Kim JW, Kim HA, Suh CH, et al. Sex hormones affect the pathogenesis and clinical characteristics of systemic lupus erythematosus. Front Med (Lausanne). 2022;9:1. doi: 10.3389/fmed.2022.906475.
   Web of Science ®Google Scholar
• Nusbaum JS, Mirza I, Shum J, et al. Sex differences in systemic lupus erythematosus: epidemiology, clinical considerations, and disease pathogenesis. Mayo Clin Proc. 2020;95(2):384–9. doi: 10.1016/j.mayocp.2019.09.012.
   PubMed Web of Science ®Google Scholar
• Gompel A. Systemic lupus erythematosus and menopause. Climacteric. 2020;23(2):109–115. doi: 10.1080/13697137.2019.1679113.
   PubMed Web of Science ®Google Scholar
• Williams WV. Hormonal contraception and the development of autoimmunity: a review of the literature. Linacre Q. 2017;84(3):275–295. doi: 10.1080/00243639.2017.1360065.
   PubMed Web of Science ®Google Scholar
• Sereda D, Werth VP. Improvement in dermatomyositis rash associated with the use of antiestrogen medication [Internet]. 2006. Available from: www.archdermatol.com.
   Google Scholar
• Gerami P, Schope JM, McDonald L, et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54(4):597–613. doi: 10.1016/j.jaad.2005.10.041.
   PubMed Web of Science ®Google Scholar
• El-Azhary RA, Pakzad SY. Amyopathic dermatomyositis: retrospective review of 37 cases. J Am Acad Dermatol. 2002;46(4):560–565. doi: 10.1067/mjd.2002.120620.
   PubMed Web of Science ®Google Scholar
• Mok CC, Ying SKY, Ma KM, et al. Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial. Lupus. 2013;22(14):1470–1478. doi: 10.1177/0961203313507987.
   PubMed Web of Science ®Google Scholar
• Zarkavelis G, Kollas A, Kampletsas E, et al. Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: a review. J Adv Res. 2016;7(5):719–726. doi: 10.1016/j.jare.2016.04.001.
   PubMed Web of Science ®Google Scholar
• Ferguson S, Trupin L, Yazdany J, et al. Who receives contraception counseling when starting new lupus medications? The potential roles of race, ethnicity, disease activity, and quality of communication. Lupus. 2016;25(1):12–17. doi: 10.1177/0961203315596079.
   PubMed Web of Science ®Google Scholar
• Clowse MEB, Li J, Talabi MB, et al. Frequency of contraception documentation in women with systemic lupus erythematosus and rheumatoid arthritis within the rheumatology informatics system for effectiveness registry. Arthritis Care Res (Hoboken). 2023;75(3):590–596. doi: 10.1002/acr.24803.
   PubMed Web of Science ®Google Scholar
• Silverstein RG, Fitz V, Thornton M, et al. Contraceptive use and counseling in patients with systemic lupus erythematosus. Contraception. 2022;105:46–50. doi: 10.1016/j.contraception.2021.08.017.
   PubMed Web of Science ®Google Scholar
• Silver R, Craigo S, Porter F, et al. Society for Maternal-Fetal Medicine Consult Series# 64: Systemic lupus erythematosus in pregnancy. Am J Obstet Gynecol. 2023;228(3):B41–B60.
   PubMed Web of Science ®Google Scholar
• Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken). 2020;72(4):461–488. doi: 10.1002/acr.24130.
   PubMed Web of Science ®Google Scholar
• Sammaritano LR. Contraception in patients with rheumatic disease. Rheum Dis Clin North Am. 2017;43(2):173–188. W.B. Saunders; doi: 10.1016/j.rdc.2016.12.001.
   PubMed Web of Science ®Google Scholar
• Al-Husayni N, Maslyanskaya S, Rubinstein TB, et al. Reproductive health care for female adolescents prescribed mycophenolate at a children’s hospital: a 10-Year retrospective cohort study. J Pediatr. 2023;253:252–258. doi: 10.1016/j.jpeds.2022.09.052.
   PubMed Web of Science ®Google Scholar
• Abdulaziz HMM, Shemies RS, Taman M, et al. Fetal proximal and distal limb anomalies following exposure to mycophenolate mofetil during pregnancy: a case report and review of the literature. Lupus. 2021;30(9):1522–1525. doi: 10.1177/09612033211021486.
   PubMed Web of Science ®Google Scholar
• Sammaritano LR. Contraception in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus. 2014;23(12):1242–1245. doi: 10.1177/0961203314528062.
   PubMed Web of Science ®Google Scholar
• Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus for the OC-SELENA trial* [internet]. N Engl J Med. 2005;353(24):2550–2558. Available from: www.nejm.org. doi: 10.1056/NEJMoa051135.
   PubMed Web of Science ®Google Scholar
• Grygiel-Górniak B, Puszczewicz MJ. The influence of endogenous and exogenous sex hormones on systemic lupus erythematosus in pre- and postmenopausal women. Prz Menopauzalny. 2014;13(4):262–266. doi: 10.5114/pm.2014.45003.
   PubMedGoogle Scholar
• Bernier MO, Mikaeloff Y, Hudson M, et al. Combined oral contraceptive use and the risk of systemic lupus erythematosus. Arthritis Rheum. 2009;61(4):476–481. doi: 10.1002/art.24398.
   PubMedGoogle Scholar
• Costenbader KH, Feskanich D, Stampfer MJ, et al. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum. 2007;56(4):1251–1262. doi: 10.1002/art.22510.
   PubMed Web of Science ®Google Scholar
• Sanchez-Guerrero J, Karlson EW, Liang MH, et al. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum. 1997;40(5):804–808. doi: 10.1002/art.1780400505.
   PubMedGoogle Scholar
• Sánchez-Guerrero J, Uribe AG, Jiménez-Santana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med. 2005;353(24):2539–2549. Available from: www.nejm.org. doi: 10.1056/NEJMoa050817.
   PubMed Web of Science ®Google Scholar
• Birru Talabi M, Himes KP, Clowse MEB. Optimizing reproductive health management in lupus and Sjogren’s syndrome. Curr Opin Rheumatol. 2021;33(6):570–578. doi: 10.1097/BOR.0000000000000839.
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention. Summary chart of U.S. medical eligibility criteria for contraceptive use [Internet]; 2020. Available from: https://www.cdc.gov/reproductivehealth/.
   Google Scholar
• Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476–485. doi: 10.1136/annrheumdis-2016-209770.
   PubMed Web of Science ®Google Scholar
• Cravioto MDC, Jiménez-Santana L, Mayorga J, et al. Side effects unrelated to disease activity and acceptability of highly effective contraceptive methods in women with systemic lupus erythematosus: a randomized, clinical trial. Contraception. 2014;90(2):147–153. doi: 10.1016/j.contraception.2014.04.001.
   PubMed Web of Science ®Google Scholar
• Wan J, Imadojemu S, Werth VP. Management of rheumatic and autoimmune blistering disease in pregnancy and postpartum. Clin Dermatol. 2016;34(3):344–352. doi: 10.1016/j.clindermatol.2016.02.006.
   PubMed Web of Science ®Google Scholar
• Tang K, Zhou J, Lan Y, et al. Pregnancy in adult-onset dermatomyositis/polymyositis: a systematic review. American J Rep Immunol. 2022;88(5):1–7. doi: 10.1111/aji.13603.
   Web of Science ®Google Scholar
• Lu Q, Long H, Chow S, et al. Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus. J Autoimmun. 2021;123:1–16. doi: 10.1016/j.jaut.2021.102707.
   Web of Science ®Google Scholar
• Donofrio MT, Moon-Grady AJ, Hornberger LK, et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. Circulation. 2014;129(21):2183–2242. doi: 10.1161/01.cir.0000437597.44550.5d.
   PubMed Web of Science ®Google Scholar
• Clowse MEB, Eudy AM, Kiernan E, et al. The prevention, screening and treatment of congenital heart block from neonatal lupus: a survey of provider practices. Rheumatology (Oxford). 2018;57(suppl_5):V9–V17. doi: 10.1093/rheumatology/key141.
   PubMedGoogle Scholar
• Hamed HO, Ahmed SR, Alzolibani A, et al. Does cutaneous lupus erythematosus have more favorable pregnancy outcomes than systemic disease? A two-center study. Acta Obstet Gynecol Scand. 2013;92(8):934–942. doi: 10.1111/aogs.12158.
   PubMed Web of Science ®Google Scholar
• Galappatthy P, Jayasinghe JDD, Paththinige SC, et al. Pregnancy outcomes and contraceptive use in patients with systemic lupus erythematosus, rheumatoid arthritis and women without a chronic illness: a comparative study. Int J Rheum Dis. 2017;20(6):746–754. doi: 10.1111/1756-185X.12996.
   PubMed Web of Science ®Google Scholar
• Rao AG, M N, Ch S, et al. Bullous systemic lupus erythematosus in a pregnant woman with anaemia coexisting with asymptomatic hepatic haemangioma. Indian J Dermatol Venereol Leprol. 2023;89(4):585–588. doi: 10.25259/IJDVL_1299_20.
   PubMed Web of Science ®Google Scholar
• Meiss L. Systemic lupus erythematosus in pregnancy. Consult Series; 2023.
   Google Scholar
• Vieitez Frade J, Filipe P. Lupus erythematosus: management of cutaneous manifestations during pregnancy. Dermatol Ther. 2022;35(6):e15486. doi: 10.1111/dth.15486.
   PubMed Web of Science ®Google Scholar
• Kirchner A, Riegert M, Lake E. Current recommendations for the systemic treatment of cutaneous lupus erythematosus during pregnancy. Cutis. 2022;109(2):90-E1. doi: 10.12788/cutis.0450.
   PubMed Web of Science ®Google Scholar
• Braunstein I, Werth V. Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy. Dermatol Ther. 2013;26(4):354–363. doi: 10.1111/dth.12076.
   PubMed Web of Science ®Google Scholar
• Dima A, Jurcut C, Chasset F, et al. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis. 2022;14:1759720X211073001. SAGE Publications Ltd doi: 10.1177/1759720X211073001.
   PubMed Web of Science ®Google Scholar
• Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus. 2001;10(6):401–404. Available from: www.arnoldpublishers.com/journals. doi: 10.1191/096120301678646137.
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf. 2017;16(3):411–419. doi: 10.1080/14740338.2017.1269168.
   PubMed Web of Science ®Google Scholar
• Barsalou J, Costedoat-Chalumeau N, Berhanu A, et al. Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus. Ann Rheum Dis. 2018;77(12):1742–1749. doi: 10.1136/annrheumdis-2018-213718.
   PubMed Web of Science ®Google Scholar
• Danve A, Perry L, Deodhar A. Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus-a case report. Semin Arthritis Rheum. 2014;44(2):195–197. doi: 10.1016/j.semarthrit.2014.05.006.
   PubMed Web of Science ®Google Scholar
• Dao KH, Bermas BL. Systemic lupus erythematosus management in pregnancy. Int J Womens Health. 2022;14:199–211. doi: 10.2147/IJWH.S282604.
   PubMed Web of Science ®Google Scholar
• Silva CA, Sultan SM, Isenberg DA. Pregnancy outcome in adult-onset idiopathic inflammatory myopathy. Rheumatology (Oxford). 2003;42(10):1168–1172. doi: 10.1093/rheumatology/keg318.
   PubMed Web of Science ®Google Scholar
• Mateus S, Malheiro M, Santos MP, et al. Dermatomyositis onset in the puerperium period. Br Med J Case Rep. 2015. Available from: http://casereports.bmj.com/.
   Google Scholar
• Chen C, Chen Y, Huang Q, et al. Case report: rapidly progressive interstitial lung disease in a pregnant patient with anti-Melanoma Differentiation-Associated gene 5 Antibody-Positive dermatomyositis. Front Immunol. 2021;12:625495. doi: 10.3389/fimmu.2021.625495.
   PubMed Web of Science ®Google Scholar
• Gupta L, Zanwar A, Ahmed S, et al. Outcomes of pregnancy in women with inflammatory myositis: a cohort study from India. J Clin Rheumatol. 2020;26(5):165–168. doi: 10.1097/RHU.0000000000000996.
   PubMed Web of Science ®Google Scholar
• Váncsa A, Ponyi A, Constantin T, et al. Pregnancy outcome in idiopathic inflammatory myopathy. Rheumatol Int. 2007;27(5):435–439. doi: 10.1007/s00296-006-0239-8.
   PubMed Web of Science ®Google Scholar
• Zhong Z, Lin F, Yang J, et al. Pregnancy in polymyositis or dermatomyositis: retrospective results from a tertiary Centre in China. Rheumatology (Oxford). 2017;56(8):1272–1275. doi: 10.1093/rheumatology/kex070.
   PubMed Web of Science ®Google Scholar
• Awatef K, Salim G, Zahra MF. A rare case of dermatomyositis revealed during pregnancy with good outcome. Pan Afr Med J. 2016;23:117. doi: 10.11604/pamj.2016.23.117.9198.
   PubMedGoogle Scholar
• Akiyama C, Shirai T, Sato H, et al. Association of various myositis-specific autoantibodies with dermatomyositis and polymyositis triggered by pregnancy. Rheumatol Int. 2022;42(7):1271–1280. doi: 10.1007/s00296-021-04851-1.
   PubMed Web of Science ®Google Scholar
• Goto H, Kawahata K, Shida A, et al. Immunosuppressive therapy before and during pregnancy may improve obstetric outcomes in pregnancy complicated by dermatomyositis with anti-MDA-5 antibody positivity: a case report. Case Rep Womens Health. 2023;37:1–5. doi: 10.1016/j.crwh.2023.e00479.
   Google Scholar
• Krones C, Vu M, Popp B, et al. New onset MDA-5 positive dermatomyositis and massive perivillous fibrin deposition in third trimester of pregnancy: a case report. J Obstet Gynaecol Res. 2023;49(6):1620–1623. doi: 10.1111/jog.15625.
   PubMed Web of Science ®Google Scholar
• Akalin T, Akkaya H, Büke B, et al. A case of New-Onset dermatomyositis in the second trimester of pregnancy: a case report and review of the literature. Case Rep Obstet Gynecol. 2016;2016:6430156–6430156. doi: 10.1155/2016/6430156.
   PubMedGoogle Scholar
• Okada K, Yamanaka K, Gyobu M, et al. Well-controlled juvenile dermatomyositis over 20 years recurred after delivery. J Dermatol. 2017;44(7):855–857. doi: 10.1111/1346-8138.13548.
   PubMed Web of Science ®Google Scholar
• Yassaee M, Kovarik CL, Werth VP. Pregnancy-associated dermatomyositis. Arch Dermatol. 2009;145(8):952–953. doi: 10.1001/archdermatol.2009.159.
   PubMedGoogle Scholar
• Iago PF, Albert SOC, Andreu FC, et al. “Pregnancy in adult-onset idiopathic inflammatory myopathy”: report from a cohort of myositis patients from a single center. Semin Arthritis Rheum. 2014;44(2):234–240. doi: 10.1016/j.semarthrit.2014.05.004.
   PubMed Web of Science ®Google Scholar
• Ochiai M, Sato E, Tanaka E, et al. Successful delivery in a patient with clinically amyopathic dermatomyositis during pregnancy despite first-trimester acute exacerbation of interstitial lung disease. Mod Rheumatol. 2017;27(2):364–368. doi: 10.3109/14397595.2014.975906.
   PubMed Web of Science ®Google Scholar
• Ito Y, Yamamoto Y, Suzuki Y, et al. Clinical and serological features and pregnancy outcomes in women with polymyositis/dermatomyositis: a case-based review. Intern Med. 2022;61(2):143–149. doi: 10.2169/internalmedicine.7924-21.
   PubMed Web of Science ®Google Scholar
• Oya K, Inoue S, Saito A, et al. Pregnancy triggers the onset of anti-transcriptional intermediary factor 1γantibody-positive dermatomyositis: a case series. Rheumatology (Oxford). 2020;59(6):1450–1451. doi: 10.1093/rheumatology/kez527.
   PubMed Web of Science ®Google Scholar
• Alonso-Espías M, Martínez-Sánchez N, Robles-Marhuenda A, et al. Diagnosis of amyopathic dermatomyositis after two intrauterine fetal deaths. Obstet Med. 2021;14(2):109–112. doi: 10.1177/1753495X20929507.
   PubMed Web of Science ®Google Scholar
• Mayu S, Isojima S, Miura Y, et al. Polymyositis-Dermatomyositis and interstitial lung disease in pregnant woman successfully treated with cyclosporine and tapered steroid therapy. Case Rep Rheumatol. 2019;2019:4914631. doi: 10.1155/2019/4914631.
   PubMedGoogle Scholar
• Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005;142(12_Part_1):953–962. Available from: https://annals.org.
   PubMed Web of Science ®Google Scholar
• Khafagy AM, Stewart KI, Christianson MS, et al. Effect of menopause hormone therapy on disease progression in systemic lupus erythematosus: a systematic review. Maturitas. 2015;81(2):276–281. doi: 10.1016/j.maturitas.2015.03.017.
   PubMed Web of Science ®Google Scholar
• Meier CR, Sturkenboom CS, Cohen A, et al. Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus. J Rheumatol. 1998;25(8):1515–1519.
   PubMed Web of Science ®Google Scholar
• Rojas-Villarraga A, Torres-Gonzalez JV, Ruiz-Sternberg ÁM. Safety of hormonal replacement therapy and oral contraceptives in systemic lupus erythematosus: a systematic review and meta-analysis. PLoS One. 2014;9(8):e104303. doi: 10.1371/journal.pone.0104303.
   PubMed Web of Science ®Google Scholar
• Sánchez-Guerrero J, González-Pérez M, Durand-Carbajal M, et al. Menopause hormonal therapy in women with systemic lupus erythematosus. Arthritis Rheum. 2007;56(9):3070–3079. doi: 10.1002/art.22855.
   PubMedGoogle Scholar
• Sanchez-Guerrero J, Liang MH, Karlson EW, et al. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med. 1995;122(6):430–433. Available from: https://annals.org.
   PubMed Web of Science ®Google Scholar
• Li R, Gebbie A, Wong R, et al. The use of sex hormones in women with rheumatological diseases. Hong Kong Med J. 2011. Available from: www.hkmj.org.
   Google Scholar
• Andrew P, Valiani S, MacIsaac J, et al. Tamoxifen-associated skin reactions in breast cancer patients: from case report to literature review. Breast Cancer Res Treat. 2014;148(1):1–5. doi: 10.1007/s10549-014-3150-0.
   PubMed Web of Science ®Google Scholar
• Chen JY, Ballou SP. The effect of antiestrogen agents on risk of autoimmune disorders in patients with breast cancer. J Rheumatol. 2015;42(1):55–59. doi: 10.3899/jrheum.140367.
   PubMed Web of Science ®Google Scholar
• Trancart M, Cavailhes A, Balme B, et al. Anastrozole-induced subacute cutaneous lupus erythematosus [3]. Br J Dermatol. 2008;158(3):628–629. doi: 10.1111/j.1365-2133.2007.08367.x.
   PubMed Web of Science ®Google Scholar
• Fumal I, Danchin A, Cosserat F, et al. Subacute cutaneous lupus erythematosus associated with tamoxifen therapy: two cases [8]. Dermatology. 2005;210(3):251–252. doi: 10.1159/000083798.
   PubMed Web of Science ®Google Scholar
• Tenti S, Giordano N, Cutolo M, et al. Primary antiphospholipid syndrome during aromatase inhibitors therapy. Medicine (Baltimore). 2019;98(13):e15052. doi: 10.1097/MD.0000000000015052.
   PubMed Web of Science ®Google Scholar
• Bowman S, Lu H. Aromatase inhibitor-induced inflammatory myopathies: a case series. Joint Bone Spine. 2022;89(2):105308. doi: 10.1016/j.jbspin.2021.105308.
   PubMed Web of Science ®Google Scholar
• Jung Y, Philip K, Cohen R, et al. Anastrozole-induced dermatitis: report of a woman with an anastrozole-associated dermatosis and a review of aromatase inhibitor-related cutaneous adverse events. Dermatol Ther (Heidelb). 2020;10(1):221–229. doi: 10.1007/s13555-020-00353-3.
   PubMed Web of Science ®Google Scholar
• Hambly R, Lally A. Hydroxychloroquine toxicity and aromatase inhibitors. Br J Dermatol. 2017;177(3):882–882. doi: 10.1111/bjd.15683.
   PubMed Web of Science ®Google Scholar
• Fisher J, Patel M, Miller M, et al. Anastrozole‐induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2008;158(3):628–629.
   Google Scholar
• Mascella F, Gianni L, Affatato A, et al. Aromatase inhibitors and anti-synthetase syndrome. Int J Immunopathol Pharmacol. 2016;29(3):494–497. doi: 10.1177/0394632016651086.
   PubMed Web of Science ®Google Scholar